Compare Johnson & Johnson (JNJ) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Tesla, Inc. — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Tesla, Inc. trades at $382.7 (market cap $1.48T). The key difference: Tesla, Inc. is far larger — about 2.4× Johnson & Johnson's market cap, and Johnson & Johnson pays a 2.09% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Tesla, Inc. for 88 Days on average.
| JNJ | TSLA | |
|---|---|---|
Market Cap | $618.09B | $1.48T |
Volume | 6,050,983 | 28,215,427 |
Sector | Health | Consumer Cyclical |
52-Week High | $278.43 | $489.88 |
52-Week Low | $186.00 | $298.16 |
Typical Hold Time | 129 Days | 88 Days |
Enterprise Value | $646.37B | $1.45T |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with $94.19B in 2025 revenue, 21.48% net income margin, and consistent earnings beats in recent quarters. Recent analyst coverage shows 52.5% buy ratings with a $286.53 consensus price target, while technical indicators point to key support at $248 and resistance at $258.
JNJ presents a compelling long-term investment case with robust profitability, diversified healthcare portfolio, and dividend stability, though near-term headwinds include patent expirations and competitive pressures. The stock's current valuation at 29.75 P/E appears reasonable given strong cash flow generation and pipeline innovation, with upside potential to analyst targets if execution continues.
Tesla trades at $375.03, down 0.68% on the day, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings miss ($0.33 actual vs. $0.50 expected) but beat expectations in the previous two quarters. Revenue declined to $94.83B in 2025 with net income margin compressing to 4%. Recent news highlights regulatory approval for driver assistance software in Europe and a potential cheaper EV launch.
Tesla faces near-term headwinds from slowing auto growth and elevated valuations (P/E 347), but long-term optimism centers on autonomous driving and energy segments. Analyst consensus price target of $441.36 suggests 18% upside, though execution risks and competition remain key concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
